written by reader $NBRV – Nabriva Therapeutics AG

by SoGiAm | September 12, 2015 10:09 am

The purpose of this thread is to provide Irregulars with a chronological discussion of $NBRV only.
Nabriva – Home: http://www.nabriva.com/[1]
$NBRV IPO[2] is tentatively September 18, 2015 at 15-17 USD and shall trade on the Nasdaq Global Market. $NBRV’s lead program is BC-3781: http://newdrugapprovals.org/2014/03/31/bc-3781-a-pleuromutilin-by-nabriva-austria-in-phase-2/[3]
My sincere thanks goes to Dr. KSS[4], Travis, Lynne and the incredible Gummune at stockgumshoe.com. Best2ALL-Ben

Endnotes:
  1. http://www.nabriva.com/: http://www.nabriva.com/
  2. IPO: https://www.stockgumshoe.com/tag/ipo/
  3. http://newdrugapprovals.org/2014/03/31/bc-3781-a-pleuromutilin-by-nabriva-austria-in-phase-2/: http://newdrugapprovals.org/2014/03/31/bc-3781-a-pleuromutilin-by-nabriva-austria-in-phase-2/
  4. Dr. KSS: https://www.stockgumshoe.com/tag/dr-kss/

Source URL: https://www.stockgumshoe.com/2015/09/microblog-nbrv-nabriva-therapeutics-ag/


27 responses to “written by reader $NBRV – Nabriva Therapeutics AG”

  1. SoGiAm says:

    $NBRV reinstated with an Outperform at Leerink. $14 PT HT https://twitter.com/odibro/status/791606157169262592

  2. SoGiAm says:

    Nabriva Achieves 60% Randomization Target in LEAP 1 Phase 3 Trial in Community Acquired Bacterial Pneumonia http://investors.nabriva.com/phoenix.zhtml?c=254099&p=irol-newsArticle&ID=2230824

  3. james says:

    Would like to hear some feedback on recent developments in this stock, FDA approval and offering

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.